Ongoing Clinical Trials for Left Ventricular Dysfunction
There is currently 1 ongoing clinical trial studying treatments for left ventricular dysfunction. This trial is investigating the safety and effectiveness of vericiguat in children with heart failure caused by problems with the heart’s ability to pump blood effectively. The study is being conducted across multiple European countries and focuses on long-term monitoring of this treatment.
Clinical trial locations
- Belgium
- Denmark
- Finland
- France
- Germany
- Hungary
- Ireland
- Italy
- Netherlands
- Poland
- Portugal
- Spain
- Sweden
Study on Vericiguat for Children with Heart Failure from Left Ventricular Systolic Dysfunction
This study is examining the long-term safety and tolerability of vericiguat in children who have heart failure caused by problems with the left side of the heart’s pumping ability. The condition affects how well the heart can pump blood throughout the body, and over time, the heart muscle may become weaker or stiffer, leading to symptoms like tiredness, difficulty breathing, and fluid buildup in the body.
Inclusion criteria: To participate in this trial, patients must have already been part of an earlier study where they received at least one dose of either vericiguat or a placebo, and they must have completed the Week 52 visit and safety follow-up period of that previous study. Patients need to be able to take medication by mouth or through a tube that goes directly to the stomach. Both boys and girls can take part, and the study includes children who may need extra care due to their age or health condition.
Exclusion criteria: Patients cannot join if they have a history of allergic reactions to vericiguat or similar medications. Those currently taking medicines that might negatively interact with the study drug are also excluded. Children with severe liver or kidney disease cannot participate, as these organs play important roles in processing medications. Patients who have had a heart attack in the last three months or have uncontrolled high blood pressure are not eligible. Girls who are pregnant or breastfeeding cannot take part, as the effects of the drug on babies are unknown. Those already participating in another clinical trial or who have any medical condition that doctors believe would make participation unsafe are also excluded.
Focus and goals: The main goal of this trial is to monitor how safe and well-tolerated vericiguat is when given to children over a long period. Researchers will carefully watch for any unexpected medical problems or side effects that might occur during treatment. They will also track how many participants need to stop taking the medication because of adverse effects. Additionally, the study will measure changes in a specific protein in the blood called N-terminal pro-brain natriuretic peptide, which helps doctors understand how well the heart is working. The study is expected to continue until April 2032, with participants taking the medication for up to 108 weeks.
Investigational drug: The medication being tested is vericiguat, also known by its code name MK-1242. It comes in two forms: tablets and an oral suspension, which is a liquid that can be swallowed. Vericiguat works by helping blood vessels relax, which makes it easier for the heart to pump blood throughout the body. It does this by stimulating an enzyme called soluble guanylate cyclase, which increases levels of molecules that improve blood flow. This can help reduce symptoms of heart failure and improve how the heart functions.
Summary
Currently, there is one ongoing clinical trial focused on left ventricular dysfunction in children. This extension study is being conducted across 13 European countries, including Hungary, Portugal, Belgium, France, Spain, Sweden, Finland, Germany, Netherlands, Italy, Denmark, Poland, and Ireland. The trial represents an important effort to understand the long-term safety of vericiguat in pediatric patients with heart failure.
The study focuses exclusively on vericiguat, a medication that works by relaxing blood vessels to improve the heart’s ability to pump blood. As an extension of a previous study, this trial allows researchers to gather valuable information about the medication’s effects over an extended period of up to 108 weeks. The wide geographic distribution of this trial across multiple European countries suggests a coordinated international effort to understand treatment options for children with this serious heart condition.